Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024
Adaptimmune Therapeutics (NASDAQ: ADAP), a cell therapy company focused on solid tumor cancers, will announce its Q3 2024 financial results and business updates after US markets close on November 13, 2024. The company will host a live webcast at 4:30 p.m. EDT (9:30 p.m. GMT). The press release will be available on Adaptimmune's corporate website, and investors can access the webcast through a provided link. Call-in options are available for US/Canada (+1-844-763-8274) and International (+1-647-484-8814) participants.
Adaptimmune Therapeutics (NASDAQ: ADAP), una società di terapia cellulare focalizzata sui tumori solidi, annuncerà i suoi risultati finanziari del Q3 2024 e aggiornamenti sul business dopo la chiusura dei mercati statunitensi il 13 novembre 2024. L'azienda ospiterà un webcast dal vivo alle 16:30 EDT (21:30 GMT). Il comunicato stampa sarà disponibile sul sito aziendale di Adaptimmune, e gli investitori potranno accedere al webcast tramite un link fornito. Sono disponibili opzioni di chiamata per i partecipanti dagli Stati Uniti/Canada (+1-844-763-8274) e internazionali (+1-647-484-8814).
Adaptimmune Therapeutics (NASDAQ: ADAP), una empresa de terapia celular centrada en cánceres de tumores sólidos, anunciará sus resultados financieros del Q3 2024 y actualizaciones empresariales después del cierre de los mercados estadounidenses el 13 de noviembre de 2024. La empresa contará con un webcast en vivo a las 4:30 p.m. EDT (9:30 p.m. GMT). El comunicado de prensa estará disponible en el sitio web corporativo de Adaptimmune, y los inversores podrán acceder al webcast a través de un enlace proporcionado. Se ofrecen opciones de llamada para participantes de EE.UU./Canadá (+1-844-763-8274) e internacionales (+1-647-484-8814).
애덤퓨진 테라퓨틱스 (NASDAQ: ADAP), 고형 종양 암에 집중하는 세포 치료 회사는 2024년 3분기 재무 결과 및 비즈니스 업데이트를 미국 시장 종료 후 2024년 11월 13일에 발표할 예정입니다. 회사는 동부 표준시 기준 오후 4시 30분 (그리니치 표준시 기준 오후 9시 30분)에 실시간 웹캐스트를 진행합니다. 보도 자료는 애덤퓨진의 기업 웹사이트에서 확인할 수 있으며, 투자자들은 제공된 링크를 통해 웹캐스트에 접속할 수 있습니다. 미국/캐나다 참가자(+1-844-763-8274) 및 국제 참가자(+1-647-484-8814)를 위한 전화 연결 옵션이 제공됩니다.
Adaptimmune Therapeutics (NASDAQ: ADAP), une entreprise de thérapie cellulaire axée sur les cancers des tumeurs solides, annoncera ses résultats financiers du T3 2024 et ses mises à jour commerciales après la fermeture des marchés américains le 13 novembre 2024. L'entreprise organisera un webinaire en direct à 16 h 30 EDT (21 h 30 GMT). Le communiqué de presse sera disponible sur le site internet de la société Adaptimmune, et les investisseurs pourront accéder au webinaire via un lien fourni. Des options d'appel sont disponibles pour les participants des États-Unis/Canada (+1-844-763-8274) et internationaux (+1-647-484-8814).
Adaptimmune Therapeutics (NASDAQ: ADAP), ein Zelltherapieunternehmen, das sich auf solide Tumorerkrankungen konzentriert, wird seine Finanzergebnisse für das 3. Quartal 2024 und Unternehmensupdates nach dem US-Marktschluss am 13. November 2024 bekanntgeben. Das Unternehmen wird um 16:30 Uhr EDT (21:30 Uhr GMT) ein Live-Webcast veranstalten. Die Pressemitteilung wird auf der Unternehmenswebsite von Adaptimmune verfügbar sein, und Investoren können über einen bereitgestellten Link auf den Webcast zugreifen. Für Teilnehmer aus den USA/Kanada (+1-844-763-8274) und internationalen Teilnehmern (+1-647-484-8814) stehen Anrufoptionen zur Verfügung.
- None.
- None.
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - October 31, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the third quarter ended September 30, 2024, after the US markets close on Wednesday, November 13, 2024. Following the announcement, the Company will host a live webcast at 4:30 p.m. EDT (9:30 p.m. GMT).
The press release will be available in the investor section of Adaptimmune's corporate website. A live webcast and replay can be accessed at https://www.gowebcasting.com/13698.
Call in information is as follows: +1-844-763-8274 (US or Canada) or +1-647-484-8814 (International). Callers should dial in 10 minutes prior to the scheduled start time and simply ask to join the Adaptimmune call.
About Adaptimmune
Adaptimmune is a clinical-stage biopharmaceutical company focused on designing, developing, and delivering cell therapies to transform the lives of people with cancer. The Company's unique engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types.
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended 31 December, 2023, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.
Adaptimmune Contact
Investor Relations
Juli P. Miller, Ph.D. - VP, Corporate Affairs and Investor Relations
M : +1 215 460 8920
Juli.Miller@adaptimmune.com
Media Relations
Dana Lynch, Senior Director of Corporate Communications
M: +1 267 990 1217
Dana.Lynch@adaptimmune.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/228443
FAQ
When will Adaptimmune (ADAP) report Q3 2024 earnings?
How can I access Adaptimmune's (ADAP) Q3 2024 earnings call?
What time is Adaptimmune's (ADAP) Q3 2024 earnings webcast?
